Chung Douglas C, Jacquelot Nicolas, Ghaedi Maryam, Warner Kathrin, Ohashi Pamela S
Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Cancers (Basel). 2022 Apr 21;14(9):2071. doi: 10.3390/cancers14092071.
Immune regulation is composed of a complex network of cellular and molecular pathways that regulate the immune system and prevent tissue damage. It is increasingly clear that innate lymphoid cells (ILCs) are also armed with immunosuppressive capacities similar to well-known immune regulatory cells (i.e., regulatory T cells). In cancer, immunoregulatory ILCs have been shown to inhibit anti-tumour immune response through various mechanisms including: (a) direct suppression of anti-tumour T cells or NK cells, (b) inhibiting T-cell priming, and (c) promoting other immunoregulatory cells. To provide a framework of understanding the role of immunosuppressive ILCs in the context of cancer, we first outline a brief history and challenges related to defining immunosuppressive ILCs. Furthermore, we focus on the mechanisms of ILCs in suppressing anti-tumour immunity and consequentially promoting tumour progression.
免疫调节由调节免疫系统并防止组织损伤的细胞和分子途径组成的复杂网络构成。越来越清楚的是,固有淋巴细胞(ILC)也具备与知名免疫调节细胞(即调节性T细胞)类似的免疫抑制能力。在癌症中,免疫调节性ILC已被证明可通过多种机制抑制抗肿瘤免疫反应,这些机制包括:(a)直接抑制抗肿瘤T细胞或自然杀伤细胞(NK细胞),(b)抑制T细胞致敏,以及(c)促进其他免疫调节细胞。为了提供一个理解免疫抑制性ILC在癌症背景下作用的框架,我们首先概述与定义免疫抑制性ILC相关的简史和挑战。此外,我们关注ILC抑制抗肿瘤免疫并进而促进肿瘤进展的机制。